These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
439 related articles for article (PubMed ID: 32190778)
21. Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation. Tokodai K; Karadagi A; Kjaernet F; Romano A; Ericzon BG; Nowak G Scand J Gastroenterol; 2019 Feb; 54(2):233-239. PubMed ID: 30999770 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of liver transplant candidates with non-alcoholic steatohepatitis. Esteban JPG; Asgharpour A Transl Gastroenterol Hepatol; 2022; 7():24. PubMed ID: 35892057 [TBL] [Abstract][Full Text] [Related]
23. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management]. Kim SK; Kim KI; Kim SR Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630 [TBL] [Abstract][Full Text] [Related]
24. Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. Lonardo A; Mantovani A; Petta S; Carraro A; Byrne CD; Targher G Nat Rev Endocrinol; 2022 Oct; 18(10):638-650. PubMed ID: 35840803 [TBL] [Abstract][Full Text] [Related]
25. Optimizing patients with non-alcoholic fatty liver disease pre-transplant. Benmassaoud A; Deschenes M; Chen T; Ghali P; Sebastiani G Can Liver J; 2020; 3(3):237-250. PubMed ID: 35992526 [TBL] [Abstract][Full Text] [Related]
26. Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times. Gitto S; Marra F; De Maria N; Bihl F; Villa E; Andreone P; Burra P Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):173-178. PubMed ID: 30791778 [TBL] [Abstract][Full Text] [Related]
28. Liver transplantation and non-alcoholic fatty liver disease. Zezos P; Renner EL World J Gastroenterol; 2014 Nov; 20(42):15532-8. PubMed ID: 25400437 [TBL] [Abstract][Full Text] [Related]
29. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Majumdar A; Tsochatzis EA Metabolism; 2020 Oct; 111S():154291. PubMed ID: 32531295 [TBL] [Abstract][Full Text] [Related]
30. Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. Patel YA; Berg CL; Moylan CA Dig Dis Sci; 2016 May; 61(5):1406-16. PubMed ID: 26815171 [TBL] [Abstract][Full Text] [Related]
31. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation. Carter D; Dieterich DT; Chang C Clin Liver Dis; 2018 Feb; 22(1):213-227. PubMed ID: 29128058 [TBL] [Abstract][Full Text] [Related]
32. Nonalcoholic steatohepatitis: the new frontier for liver transplantation. Bzowej NH Curr Opin Organ Transplant; 2018 Apr; 23(2):169-174. PubMed ID: 29356708 [TBL] [Abstract][Full Text] [Related]
33. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177 [TBL] [Abstract][Full Text] [Related]
34. NASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed? Canbay A; Sowa JP; Syn WK; Treckmann J Visc Med; 2016 Aug; 32(4):234-238. PubMed ID: 27722159 [TBL] [Abstract][Full Text] [Related]
35. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189 [TBL] [Abstract][Full Text] [Related]
36. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156 [TBL] [Abstract][Full Text] [Related]
37. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [TBL] [Abstract][Full Text] [Related]
38. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Perumpail RB; Wong RJ; Ahmed A; Harrison SA Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831 [TBL] [Abstract][Full Text] [Related]